Pfizer Inc.
PFE
$23.35
$0.231.00%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/30/2025 | 12/31/2024 | 09/29/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 62.46B | 63.63B | 60.43B | 56.22B | 55.95B |
| Total Other Revenue | -- | 2.17B | 4.08B | 4.08B | 4.08B |
| Total Revenue | 62.46B | 63.63B | 60.43B | 56.22B | 55.95B |
| Cost of Revenue | 15.97B | 16.42B | 11.74B | 15.78B | 16.08B |
| Gross Profit | 46.49B | 47.21B | 48.69B | 40.45B | 39.87B |
| SG&A Expenses | 14.32B | 14.76B | 14.15B | 14.15B | 13.92B |
| Depreciation & Amortization | 5.19B | 5.29B | 5.19B | 5.06B | 4.94B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.00B | 47.28B | 41.68B | 45.69B | 45.60B |
| Operating Income | 16.46B | 16.34B | 18.75B | 10.53B | 10.34B |
| Income Before Tax | 7.39B | 8.02B | 3.90B | -4.16B | -1.79B |
| Income Tax Expenses | -510.00M | -28.00M | -402.00M | -1.60B | -1.54B |
| Earnings from Continuing Operations | 7.90K | 8.05K | 4.31K | -2.56K | -254.00 |
| Earnings from Discontinued Operations | 16.00M | 11.00M | -22.00M | -2.00M | -21.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -29.00M | -31.00M | -32.00M | -30.00M | -34.00M |
| Net Income | 7.88B | 8.03B | 4.25B | -2.60B | -309.00M |
| EBIT | 16.46B | 16.34B | 18.75B | 10.53B | 10.34B |
| EBITDA | 23.34B | 23.34B | 25.63B | 17.21B | 16.86B |
| EPS Basic | 1.39 | 1.42 | 0.75 | -0.46 | -0.06 |
| Normalized Basic EPS | 1.58 | 1.54 | 1.88 | 1.07 | 1.12 |
| EPS Diluted | 1.39 | 1.42 | 0.74 | -0.47 | -0.07 |
| Normalized Diluted EPS | 1.57 | 1.53 | 1.87 | 1.07 | 1.11 |
| Average Basic Shares Outstanding | 22.68B | 22.66B | 22.64B | 22.62B | 22.60B |
| Average Diluted Shares Outstanding | 22.81B | 22.80B | 22.75B | 22.69B | 22.70B |
| Dividend Per Share | 1.69 | 1.68 | 1.67 | 1.66 | 1.65 |
| Payout Ratio | 121.49% | 118.44% | 222.18% | -361.50% | -3,014.89% |